Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Assets (2016 - 2025)

Northwest Biotherapeutics' Other Non-Current Assets history spans 16 years, with the latest figure at $356000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $356000.0 for Q4 2025, down 2.47% from a year ago — trailing twelve months through Dec 2025 was $356000.0 (down 2.47% YoY), and the annual figure for FY2025 was $356000.0, down 2.47%.
  • Other Non-Current Assets for Q4 2025 was $356000.0 at Northwest Biotherapeutics, down from $358000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q2 2021 to a low of $339000.0 in Q3 2022.
  • The 5-year median for Other Non-Current Assets is $362500.0 (2023), against an average of $499650.0.
  • The sharpest move saw Other Non-Current Assets skyrocketed 44.77% in 2021, then tumbled 68.71% in 2022.
  • Year by year, Other Non-Current Assets stood at $1.0 million in 2021, then crashed by 66.7% to $345000.0 in 2022, then rose by 4.64% to $361000.0 in 2023, then rose by 1.11% to $365000.0 in 2024, then decreased by 2.47% to $356000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $356000.0, $358000.0, and $370000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.